Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in B-Cell ALL with Positive MRD
NCT02458014Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2015
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2015; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02458014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02458014.